These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 10377216

  • 1. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM, Ji Z, Pinon DI, Henne RM, Lybrand TP, Miller LJ.
    J Med Chem; 1999 Jun 17; 42(12):2105-11. PubMed ID: 10377216
    [Abstract] [Full Text] [Related]

  • 2. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M, Liu G, Pinon DI, Miller LJ.
    Biochemistry; 2005 May 03; 44(17):6693-700. PubMed ID: 15850403
    [Abstract] [Full Text] [Related]

  • 3. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D.
    Mol Pharmacol; 1994 Apr 03; 45(4):599-607. PubMed ID: 8183238
    [Abstract] [Full Text] [Related]

  • 4. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor.
    Smeets RL, Fouraux MA, Pouwels W, van Emst-de Vries SE, Ronken E, De Pont JJ, Willems PH.
    Br J Pharmacol; 1998 Jul 03; 124(5):935-45. PubMed ID: 9692779
    [Abstract] [Full Text] [Related]

  • 5. The gall bladder cholecystokinin receptor exists in two guanine nucleotide-binding protein-regulated affinity states.
    Molero X, Miller LJ.
    Mol Pharmacol; 1991 Feb 03; 39(2):150-6. PubMed ID: 1899903
    [Abstract] [Full Text] [Related]

  • 6. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.
    Mol Pharmacol; 2004 Jan 03; 65(1):28-35. PubMed ID: 14722234
    [Abstract] [Full Text] [Related]

  • 7. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.
    Dong M, Hadac EM, Pinon DI, Miller LJ.
    Mol Pharmacol; 2005 Jun 03; 67(6):1892-900. PubMed ID: 15774770
    [Abstract] [Full Text] [Related]

  • 8. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
    Anders J, Blüggel M, Meyer HE, Kühne R, ter Laak AM, Kojro E, Fahrenholz F.
    Biochemistry; 1999 May 11; 38(19):6043-55. PubMed ID: 10320330
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis.
    Dong M, Ding XQ, Pinon DI, Hadac EM, Oda RP, Landers JP, Miller LJ.
    J Biol Chem; 1999 Feb 19; 274(8):4778-85. PubMed ID: 9988716
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular approximations between residues 21 and 23 of secretin and its receptor: development of a model for peptide docking with the amino terminus of the secretin receptor.
    Dong M, Lam PC, Gao F, Hosohata K, Pinon DI, Sexton PM, Abagyan R, Miller LJ.
    Mol Pharmacol; 2007 Aug 19; 72(2):280-90. PubMed ID: 17475809
    [Abstract] [Full Text] [Related]

  • 15. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW, Nikiforovich GV, Haskell-Luevano C, Fang SN, Zalewska T, Stropova D, Yamamura HI, Hruby VJ.
    J Med Chem; 1996 Sep 27; 39(20):4120-4. PubMed ID: 8831778
    [Abstract] [Full Text] [Related]

  • 16. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
    Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ.
    J Biol Chem; 2001 Feb 09; 276(6):4236-44. PubMed ID: 11050076
    [Abstract] [Full Text] [Related]

  • 17. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz JA, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy AD.
    Protein Sci; 1999 Nov 09; 8(11):2347-54. PubMed ID: 10595537
    [Abstract] [Full Text] [Related]

  • 18. Molecular approximation between residue 10 of secretin and its receptor demonstrated by photoaffinity labeling.
    Dong M, Miller LJ.
    Ann N Y Acad Sci; 2006 Jul 09; 1070():243-7. PubMed ID: 16888174
    [Abstract] [Full Text] [Related]

  • 19. The efficiency of covalent labeling of the pancreatic cholecystokinin receptor using a battery of crosslinkable and photolabile probes.
    Klueppelberg UG, Powers SP, Miller LJ.
    Receptor; 2006 Jul 09; 1(1-2):1-11. PubMed ID: 2152369
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.